Clinical trials
Unresectable Hepatocellular Carcinoma clinical trials
Below are recruiting unresectable hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 160 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07607769Recruiting
Tremelimumab and Durvalumab for Untreated Advanced Liver Cancer
This Italian study follows patients with advanced liver cancer (hepatocellular carcinoma) who receive a combination immunotherapy treatment called STRIDE for the first time. The trial tracks how well the treatment works, how it affects quality of life, and its safety in people with moderate to severe liver disease.
AnconaAges 18–100 - NCT06187961RecruitingPhase 2
Combination therapy for liver cancer that cannot be removed with surgery
This study tests a combination of three treatments (HAIC, lenvatinib, and cadonilimab) as a way to shrink liver tumors that cannot be removed with surgery. The goal is to make the tumors smaller so they might be removed later, and to see how safe and effective this combination is.
Wuhan, HubeiAges 18 years+ - NCT07782632Recruiting
Imaging scans to predict immunotherapy response in liver cancer
This study looks at how doctors can use imaging scans to predict how well immunotherapy will work for people with liver cancer that cannot be removed by surgery. Participants must have already received immunotherapy and have had baseline scans.
Hefei, AnhuiAges 18–75 - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT07291076RecruitingPhase 1/Phase 2
Study of Pumitamig with Ipilimumab for first-line advanced liver cancer
This trial tests a new drug called pumitamig, either alone or with another drug (ipilimumab), for people with advanced liver cancer that hasn't been treated yet. The goal is to see if these drugs can help shrink or control the cancer.
Duarte, CaliforniaAges 18 years+ - NCT07209813RecruitingPhase 2
Immunotherapy plus TACE for liver cancer
This trial tests a new immunotherapy drug (GKL-006) combined with a standard treatment called TACE (which blocks blood flow to the tumor) for people with liver cancer that cannot be removed by surgery. The goal is to see if adding this drug helps shrink tumors more than TACE alone.
Beijing, Beijing MunicipalityAges 18–80 - NCT07227012RecruitingPhase 1/Phase 2
Study of a new drug for advanced liver cancer
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
Irvine, CaliforniaAges 18 years+ - NCT06880523RecruitingPhase 2
Adding lenvatinib to immunotherapy for liver cancer
This trial tests adding lenvatinib (a targeted therapy pill) to a combination of two immunotherapy drugs (durvalumab and tremelimumab) for people with liver cancer that cannot be removed by surgery. The goal is to see if the three-drug approach works better than the two immunotherapy drugs alone.
Calgary, AlbertaAges 18 years+ - NCT06788353Recruiting
Liver cancer treatment study for patients not eligible for surgery
This trial is collecting information on how well a treatment (likely TACE, a procedure to block the tumor's blood supply) works for people with liver cancer that cannot be removed by surgery. It aims to see how safe and effective it is for patients who haven't had treatment before or who have a first recurrence.
Guangzhou, GuangdongAges 18–75 - NCT05917431RecruitingPhase 2
Radiation plus immunotherapy and targeted pills for liver cancer
This Phase 2 trial studies whether a combination of SBRT (focused radiation) plus tislelizumab and regorafenib can control unresectable or limited-spread liver cancer. It may help by attacking tumors in the liver and immune system to improve shrinkage and control of disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05096715RecruitingPhase 1
Testing atezolizumab plus bevacizumab with SBRT for advanced liver cancer
This Phase 1 trial tests how well a combination treatment works for liver cancer that cannot be removed with surgery or other local treatments. It combines two immune/targeted medicines with a focused type of radiation (SBRT) to control the tumors.
Boston, MassachusettsAges 18 years+ - NCT06133062RecruitingPhase 2
Study of atezolizumab, bevacizumab, and proton therapy for advanced liver cancer
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) plus targeted proton radiation for liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink tumors and improve outcomes for people with intermediate or advanced stage liver cancer.
Taoyuan City, TaiwanAges 18 years+ - NCT06737913RecruitingPhase 2
Study of adebrelimab and bevacizumab with liver chemo for advanced liver cancer
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (bevacizumab) given through a vein or directly into the liver artery, along with standard chemotherapy directly into the liver artery, for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink or control the cancer.
Lanzhou, GansuAges 18 years+ - NCT05911633Recruiting
Doxorubicin beads for liver cancer that cannot be cut out
This trial tests BioPearl™ “microspheres” loaded with doxorubicin, delivered to the liver, for people with unresectable hepatocellular carcinoma (HCC). It may help shrink or control liver tumors when surgery or curative treatment isn’t possible.
BrusselsAges 18 years+ - NCT06485466RecruitingPhase 3
TACE plus Camrelizumab and Apatinib for liver cancer that can't be removed by surgery
This trial tests combining a liver-directed treatment (TACE) with two medications (Camrelizumab and Apatinib) to see if it works better for people with liver cancer that cannot be surgically removed. It is for people who have not had any previous treatment for their cancer.
Chengdu, SichuanAges 18–80 - NCT07478302RecruitingPhase 1
A study of two drugs for untreated advanced liver cancer
This trial tests a combination of two medications, SHR-2524 and bevacizumab, as a first treatment for people with advanced hepatocellular carcinoma (a type of liver cancer) that has not been treated with cancer drugs before. The goal is to see if this combination can help shrink or control the cancer.
Fuzhou, FujianAges 18 years+ - NCT07175441RecruitingPhase 2
Testing a new drug combo for advanced liver cancer
This trial tests a new drug called RBS2418 added to two immunotherapy medicines (tremelimumab and durvalumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination helps patients who are starting their first treatment for this stage of liver cancer.
Baltimore, MarylandAges 18 years+ - NCT06909708Recruiting
Comparing two liver cancer treatments for unresectable tumors
This trial compares two treatments for liver cancer that cannot be removed by surgery: SIRT (a type of internal radiation) and cTACE (a type of targeted chemo). It aims to see which is more effective for patients with limited tumor spread and good liver function.
Nanjing, JiangsuAges 18 years+ - NCT06360042RecruitingPhase 2
Immunotherapy plus anti-angiogenic drugs for advanced liver cancer
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07482059RecruitingPhase 1/Phase 2
Combination therapy for advanced liver cancer
This trial tests a combination of treatments for liver cancer that cannot be removed by surgery. It uses a special radiation therapy called Y90 along with other drugs to see if they work better together.
Chengdu, SichuanAges 18–80 - NCT07408804Recruiting
Lenvatinib alone vs. with chemoembolization for liver cancer
This trial compares the combination of two treatments—chemoembolization (TACE) and lenvatinib—against lenvatinib alone for people with liver cancer that cannot be removed by surgery. It aims to see if the combination works better.
DhakaAges 18–75 - NCT07495735Recruiting
Predicting response to liver cancer treatment
This study is looking at how well a combination of two drugs (atezolizumab and bevacizumab) works for people with liver cancer that can't be removed by surgery. The goal is to learn how to predict the best response using lab tests and CT scans.
Wenzhou, ZhejiangAges 18 years+ - NCT05168163RecruitingPhase 2
Atezolizumab plus targeted drug for advanced liver cancer
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
Scottsdale, ArizonaAges 18 years+ - NCT07179900RecruitingPhase 2
Radiation plus two drugs for liver cancer that can't be removed
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
Shijiazhuang, HebeiAges 18 years+
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Unresectable Hepatocellular Carcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for unresectable hepatocellular carcinoma?
- Yes. Clin2 currently lists 160 recruiting unresectable hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a unresectable hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a unresectable hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.